Curanex Pharmaceuticals Inc. SEC filings document a development-stage pharmaceutical issuer advancing botanical drug programs, led by Phyto-N. Its disclosures include Regulation FD reports on pipeline focus, preclinical and regulatory-development topics, and formal updates involving cancer cachexia and inflammatory-disease indications.
The company’s filings also cover Nasdaq continued-listing notices, common-stock capital structure, unregistered equity issuances, IPO-related share activity, related-party promissory notes, executive employment agreements, compensatory arrangements and governance matters. Periodic-report records include Form 12b-25 late-filing notices for quarterly reporting obligations.
Curanex Pharmaceuticals Inc. provided a first quarter 2026 business update focused on Phyto-N, its lead drug candidate for ulcerative colitis. The company completed a GMP-compliant pilot-scale manufacturing batch and a 28-day dose-range finding toxicology study in rats and dogs, with no treatment-related adverse findings of toxicological significance reported at any dose level, including the maximum feasible dose. These results are intended to support GLP toxicology and other IND-enabling studies for a planned Investigational New Drug submission to the FDA in the fourth quarter of 2026. Curanex also broadened its pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for it, citing a global market estimated at about $2.54 billion in 2024 and projected to reach $3.90 billion by 2033. As of March 31, 2026, the company held approximately $4.0 million in cash and cash equivalents to fund upcoming development activities.
Curanex Pharmaceuticals reported a net loss of $3.15 million for the three months ended March 31, 2026, sharply higher than $0.14 million a year earlier, as it ramped spending on its botanical drug pipeline.
General and administrative expenses rose to $0.93 million, while research and development reached $2.26 million, driven by IND‑enabling studies for lead candidate Phyto‑N and other programs. The company held cash and cash equivalents of $4.02 million and reported total assets of $8.41 million, with $3.91 million recorded as prepaid R&D to CROs and CDMOs.
Management concluded prior substantial doubt about going concern has been alleviated, citing IPO‑related net proceeds of roughly $15.3 million and projected liquidity for at least 12 months. Curanex advanced manufacturing and toxicology milestones for Phyto‑N, added cancer cachexia as a new core indication, but also disclosed ongoing Nasdaq minimum bid price non‑compliance that may require a reverse stock split to avoid potential delisting by November 2, 2026.
Curanex Pharmaceuticals Inc. received an extension from Nasdaq to regain compliance with the $1.00 minimum bid price required for its common stock to remain listed on the Nasdaq Capital Market. The company now has until November 2, 2026 to lift its closing bid price to at least $1.00 for 10 consecutive business days. Curanex is monitoring its share price and may implement a reverse stock split to meet this requirement, but there is no assurance it will succeed, and failure to comply could result in delisting, subject to a potential appeal to a Nasdaq Hearings Panel.
Curanex Pharmaceuticals Inc. is expanding its drug development pipeline to add cancer cachexia as a new core indication alongside six existing targets such as ulcerative colitis and nonalcoholic fatty liver disease. Cancer cachexia is a severe cancer‑related wasting syndrome with no approved U.S. therapies.
The company cites significant unmet medical need and growing recognition of cancer cachexia, which may affect up to 80% of patients with advanced cancer depending on type and treatment response. Curanex references research estimating the global cancer cachexia market at about $2.54 billion in 2024, projected to reach $3.90 billion by 2033.
Curanex’s lead candidate, Phyto‑N, remains in FDA‑required preclinical studies ahead of a planned IND submission for ulcerative colitis, while management evaluates broader opportunities in serious diseases involving inflammation, metabolic dysfunction and physical decline.
Curanex Pharmaceuticals files its annual report describing an early-stage strategy built around Phyto-N, a proprietary botanical drug candidate for inflammatory diseases. The company is still pre-revenue and remains in preclinical development.
Curanex targets a first Investigational New Drug filing for ulcerative colitis in the fourth quarter of 2026, followed by a Phase 1 trial planned in Australia. Phyto-N is being studied across six indications, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, supported by animal data and a pilot-scale GMP manufacturing batch completed in 2026.
As of March 30, 2026, the company had 28,364,812 common shares outstanding, following an initial public offering completed in 2025. Management emphasizes substantial scientific, regulatory, and financing risks before any potential commercialization.
Curanex Pharmaceuticals Inc entered into new executive employment agreements for its two top leaders. On March 2, 2026, the company signed a CEO agreement with Jun Liu, effective March 1, 2026, with a base salary of $393,600 per year and an automobile lease benefit of $3,998 per month. The agreement runs for four years and can be renewed for one-year periods by mutual consent, and includes equity incentive eligibility and standard employee benefits.
Curanex also signed a COO agreement with Dr. Liqin Xie, effective March 1, 2026, with a base salary of $180,000 per year, equity plan eligibility, and standard benefits. His employment is at will and can be ended by either side at any time. Both executives receive three months of salary, continued benefits, and immediate vesting of unvested options or restricted shares if terminated without cause, or for the CEO, if he resigns for defined good reason. The agreements include non-compete, non-solicitation, and confidentiality covenants.
Curanex Pharmaceuticals Inc. (CURX) completed its Nasdaq IPO in August 2025, raising approximately $13.24M in net proceeds, plus $2.07M from the underwriters’ over-allotment exercise. As of September 30, 2025, the company held $5,830,537 in cash and had total assets of about $14.5M, driven largely by $8.47M of prepaid R&D with CROs and CDMOs.
The business remains pre-revenue and reported a net loss of $954,059 for the quarter and $1,151,988 for the nine months ended September 30, 2025, mainly from general and administrative costs of $466,863 and R&D expenses of $679,574. Management now concludes prior going concern doubts are alleviated based on IPO funding, though the company disclosed a Nasdaq notice on November 5, 2025 for its share price being below $1.00, with a compliance period through May 4, 2026.
Curanex Pharmaceuticals (CURX) reported a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive business days. Trading on the Nasdaq Capital Market continues under “CURX”.
The company has a 180‑day compliance period until May 4, 2026 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days (subject to Nasdaq staff discretion). If unmet, Curanex may receive an additional 180 days if it satisfies other initial listing standards and notifies Nasdaq of an intent to cure, which may include a reverse stock split. Failing that, the stock would be subject to delisting.
Curanex Pharmaceuticals Inc reported two key actions. The company issued 28,312 unregistered shares of common stock to investor Xiaohong Song under a prior subscription agreement, in exchange for $200,000 that had been subscribed contingent on its initial public offering. This share grant represents 0.1% of 28,312,500 total common shares outstanding at the time of issuance and was made under a private offering exemption.
Curanex also fully repaid two insider loans from Dian Ying Jing, the CEO’s spouse, totaling $400,000 of principal. It paid $408,537.32 in aggregate, including $8,537.32 of accrued interest at a 4.34% annual rate, and did so ahead of the 2027 maturity dates. This prepayment eliminated all of the company’s outstanding debt and removed approximately $26,182.68 of future interest charges that would have accrued through maturity.